155 related articles for article (PubMed ID: 11266079)
1. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
Shimada T; Tsumura F; Yamazaki H; Guengerich FP; Inoue K
Pharmacogenetics; 2001 Mar; 11(2):143-56. PubMed ID: 11266079
[TBL] [Abstract][Full Text] [Related]
2. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
3. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
4. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
5. Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae.
Hanioka N; Okumura Y; Saito Y; Hichiya H; Soyama A; Saito K; Ueno K; Sawada J; Narimatsu S
Biochem Pharmacol; 2006 Apr; 71(9):1386-95. PubMed ID: 16527257
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
7. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
8. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
[TBL] [Abstract][Full Text] [Related]
10. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
11. Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene.
Inoue K; Yamazaki H; Shimada T
Arch Toxicol; 2000 Sep; 74(7):372-8. PubMed ID: 11043492
[TBL] [Abstract][Full Text] [Related]
12. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CYP2D6 Protein Expression and Activity in the Small Intestine to Determine Its Metabolic Capability in the Japanese Population.
Kawakami M; Takenoshita-Nakaya S; Takeba Y; Nishimura Y; Oda M; Watanabe M; Ohta Y; Kobayashi S; Ohtsubo T; Kobayashi S; Uchida N; Matsumoto N
Biol Pharm Bull; 2017 Sep; 40(9):1344-1351. PubMed ID: 28626197
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes.
Narimatsu S; Takemi C; Tsuzuki D; Kataoka H; Yamamoto S; Shimada N; Suzuki S; Satoh T; Meyer UA; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):172-8. PubMed ID: 12235248
[TBL] [Abstract][Full Text] [Related]
16. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
Okubo M; Morita S; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):93-102. PubMed ID: 26856541
[TBL] [Abstract][Full Text] [Related]
17. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding.
Foti RS; Fisher MB
Drug Metab Dispos; 2004 Mar; 32(3):295-304. PubMed ID: 14977863
[TBL] [Abstract][Full Text] [Related]
18. Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.
Cai J; Dai DP; Geng PW; Wang SH; Wang H; Zhan YY; Huang XX; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2016 Mar; 118(3):190-9. PubMed ID: 26310775
[TBL] [Abstract][Full Text] [Related]
19. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
20. The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes.
Coleman T; Spellman EF; Rostami-Hodjegan A; Lennard MS; Tucker GT
Drug Metab Dispos; 2000 Sep; 28(9):1094-9. PubMed ID: 10950855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
